EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieVergleichsstudie

A Randomized Clinical Trial to Compare Moxifloxacin Versus Azithromycin for the Treatment of Mycoplasma genitalium : The FARTHEST Study

Roberto Rossotti iD, Chiara Baiguera, Davide Paolo Bernasconi iD, Nicholas Brian Bana, Alice Nava iD, Gabriele Cavazza iD, Giulia Jole Burastero, Leonardo Francesco Rezzonico, Elena Simoncini, Elisa Di Gennaro, Leonardo Luzi iD, Diana Fanti und 3 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag317 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Roberto Rossotti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. Hauptthemen laut MEDLINE: Mycoplasma genitalium, Moxifloxacin, Azithromycin, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycoplasma genitalium (MG) is increasingly characterized by high rates of macrolide and fluoroquinolone resistance. International guidelines recommend resistance-guided therapy; however, access to genotypic testing is limited, and randomized trial evidence is lacking. We assessed the efficacy of moxifloxacin and azithromycin without resistance assays.

Methods

This monocentric, open-label, superiority, randomized controlled trial enrolled adults with MG infection detected by multiplex PCR, randomized 1:1 to receive moxifloxacin 400 mg daily for 10 days or azithromycin 500 mg daily for 6 days. A test of cure was performed ≥28 days after treatment completion. The primary endpoint was microbiological cure in the intention-to-treat (ITT) and per-protocol (PP) populations. Subgroup analyses assessed symptomatic versus asymptomatic infections, doxycycline exposure, re-treatment, and sexual behavior.

Results

Among 358 randomized participants, 87.0% of those treated with moxifloxacin and 61.2% of those treated with azithromycin achieved microbiological cure in the ITT analysis (absolute risk difference 25.8%, 95% CI 16.5, 35.2). The superiority of moxifloxacin was confirmed in the ITT and PP populations. Moxifloxacin remained superior across most subgroups, whereas azithromycin showed comparable efficacy only among heterosexual individuals. Doxycycline coadministration did not improve outcomes. Both regimens were well tolerated, with only one case of discontinuation.

Conclusions

Moxifloxacin demonstrated superior efficacy compared to azithromycin for treating MG infection in the absence of resistance testing. These randomized data support the use of moxifloxacin as a first-line option when resistance assays are unavailable and may inform treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycoplasma genitaliumMoxifloxacinAzithromycinAnti-Bacterial AgentsMycoplasma InfectionsHumansFemaleAdultMaleMiddle AgedTreatment OutcomeYoung AdultDrug Resistance, BacterialDoxycyclineAdolescent

Stichwörter der Autor:innen

Mycoplasma genitaliumantimicrobial resistanceazithromycindoxycyclinemoxifloxacin

Substanzen

MoxifloxacinAzithromycinAnti-Bacterial AgentsDoxycycline

Autor:innen und Institutionen

  • Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
  • Bicocca Bioinformatics Biostatistics and Bioimaging Center B4, University of Milano-Bicocca, Milan, Italy.
  • Department of Research Innovation and Technology Transfer, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Clinical Microbiology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.

ORCID-Profile: Roberto Rossotti, Davide Paolo Bernasconi, Alice Nava, Gabriele Cavazza, Leonardo Luzi, Giovanna Travi, Marco Merli, Massimo Puoti

Zitieren

APA

Rossotti, R., Baiguera, C., Bernasconi, D. P., Bana, N. B., Nava, A., Cavazza, G., Burastero, G. J., Rezzonico, L. F., Simoncini, E., Di Gennaro, E., Luzi, L., Fanti, D., Travi, G., Merli, M., & Puoti, M. (2026). A Randomized Clinical Trial to Compare Moxifloxacin Versus Azithromycin for the Treatment of Mycoplasma genitalium : The FARTHEST Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag317

Vancouver

Rossotti R, Baiguera C, Bernasconi DP, Bana NB, Nava A, Cavazza G, et al. A Randomized Clinical Trial to Compare Moxifloxacin Versus Azithromycin for the Treatment of Mycoplasma genitalium : The FARTHEST Study. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag317

BibTeX
@article{Rossotti2026,
  author = {Rossotti, Roberto and Baiguera, Chiara and Bernasconi, Davide Paolo and Bana, Nicholas Brian and Nava, Alice and Cavazza, Gabriele and Burastero, Giulia Jole and Rezzonico, Leonardo Francesco and Simoncini, Elena and Di Gennaro, Elisa and Luzi, Leonardo and Fanti, Diana and Travi, Giovanna and Merli, Marco and Puoti, Massimo},
  title = {A Randomized Clinical Trial to Compare Moxifloxacin Versus Azithromycin for the Treatment of Mycoplasma genitalium : The FARTHEST Study},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag317}
}
Kostenlos starten →